09:13 AM EDT, 09/17/2024 (MT Newswires) -- Hoth Therapeutics ( HOTH ) said Tuesday that its Alzheimer's drug, HT-ALZ, showed positive preclinical results by significantly lowering astrocyte activity in key brain areas of Alzheimer's model mice, potentially improving cognitive function.

The company said it plans to continue advancing HT-ALZ through additional studies and clinical trials.

It said it is currently conducting a secondary analysis to see if treatment affects the size or total number of astrocytes.

Shares of the company were up nearly 17% in recent Tuesday premarket activity.

Price: 1.1800, Change: +0.17, Percent Change: +16.83